Company profile
AN2 THERAPEUTICS, INC.
NASDAQ:ANTXBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| EPETRABOROLE | phase2_3 | — | 10 | completed, terminated |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05283746 | phase1 | completed | 2022-02-21 | 2022-06-10 | AN2 Therapeutics, Inc | A Study of Epetraborole Tablets in Subjects With Degrees of Renal Function |
| NCT05995444 | phase1 | completed | 2023-06-05 | 2023-07-26 | AN2 Therapeutics, Inc | A Study to Assess the Effects of Epetraborole on the QT Interval in Healthy Adult Subjects |
| NCT07024589 | phase1 | completed | 2025-08-04 | 2026-03-14 | AN2 Therapeutics, Inc | First-in-Human Trial of Oral AN2-502998 |
| NCT04892641 | phase1 | completed | 2021-06-10 | 2022-02-26 | AN2 Therapeutics, Inc | Phase 1 Study of Epetraborole Tablets |
| NCT05327803 | phase2_3 | terminated | 2022-05-20 | 2024-12-18 | AN2 Therapeutics, Inc | Study of Epetraborole in Patients With Treatment-refractory MAC Lung Disease |
FDA applications (0)
No records yet.